Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-26 Purchase | 2024-03-28 4:30 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 8,429 | $21.5 | $181,224 | 6,809,429 (Indirect) | View |
| 2024-03-26 Sale | 2024-03-27 4:30 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 190,476 | $21.5 | $4,095,234 | 970,229 (Indirect) | View |
| 2024-02-13 Purchase | 2024-02-21 5:00 pm | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 5,000 | $19 | $95,000 | 24,878 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-01 Option Award | 2024-04-02 4:30 pm | N/A 2034-04-01 | NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer | 250,000 | $0 | 250,000 (Direct) | View |
| 2024-03-26 Exercise | 2024-03-27 4:30 pm | N/A 2031-07-06 | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 201,673 | $0 | 970,229 (Indirect) | View |
| 2024-03-26 Tax Withholding | 2024-03-27 4:30 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 11,197 | $22.72 | 970,229 (Indirect) | View |
Ownership(A) | 2024-01-25 5:00 pm | 2022-12-22 2027-11-23 | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 0 | $0 | 100,000 (Direct) | View |
Ownership(A) | 2024-01-25 5:00 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 0 | $0 | 234,683 (Direct) | View |
| 2024-01-04 Option Award | 2024-01-08 7:43 pm | N/A 2034-01-04 | NewAmsterdam Pharma Co N.V. | NAMS | Lewis William Director | 100,000 | $0 | 100,000 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:26 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 150,494 | $0 | 150,494 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:21 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 323,771 | $0 | 323,771 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:19 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | van der Kamp Hilde Johanna Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:17 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:17 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 500,000 | $0 | 500,000 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:14 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 1,039,939 | $0 | 1,039,939 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:13 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Smither John W Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 5:10 pm | N/A 2034-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 80,000 | $0 | 80,000 (Direct) | View |
Ownership | 2024-01-02 4:00 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 0 | $0 | 11,831,461 (Indirect) | View |
Ownership | 2023-12-29 5:09 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Bain Capital Life Sciences Investors LLC BCLS Fund III Investments LP Bain Capital Life Sciences III General Partner LLC Bain Capital Life Sciences Fund III L.P. BCLS Fund III Investments GP LLC BCLS II Investco LP BCLS II Investco (GP) LLC Bain Capital Life Sciences Fund II L.P. Bain Capital Life Sciences Investors II LLC BCIP Life Sciences Associates LP 10% Owner | 0 | $0 | 10,573,913 (Indirect) | View |
Ownership | 2023-12-29 4:30 pm | N/A 2033-01-14 | NewAmsterdam Pharma Co N.V. | NAMS | Smither John W Director | 0 | $0 | 18,600 (Direct) | View |
Ownership | 2023-12-29 4:30 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 0 | $0 | 7,301,333 (Indirect) | View |
Ownership | 2023-12-29 4:30 pm | N/A 2033-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 0 | $0 | 2,620,975 (Direct) | View |
Ownership | 2023-12-29 4:30 pm | N/A 2033-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 0 | $0 | 1,378,172 (Direct) | View |
Ownership | 2023-12-29 4:30 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 0 | $0 | 5,259,853 (Direct) | View |
Ownership | 2023-12-29 4:30 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 0 | $0 | 237,647 (Direct) | View |
Ownership | 2023-12-29 4:30 pm | N/A 2033-05-18 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 0 | $0 | 916,222 (Direct) | View |
Ownership | 2023-12-29 4:30 pm | N/A 2033-11-01 | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 0 | $0 | 824,697 (Direct) | View |
Ownership | 2023-12-29 4:30 pm | N/A 2033-04-01 | NewAmsterdam Pharma Co N.V. | NAMS | van der Kamp Hilde Johanna Director | 0 | $0 | 18,000 (Direct) | View |